Oliceridine in the Treatment of Moderate to Severe Acute Pain

References

• Gan TJ , HabibAS , MillerTE , WhiteW , ApfelbaumJL. Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. Curr. Med. Res. Opin.30(1), 149–160 (2014).
   PubMed Web of Science ®Google Scholar
• Gan TJ . Poorly controlled postoperative pain: prevalence, consequences, and prevention. J. Pain Res.10, 2287–2298 (2017).
   PubMed Web of Science ®Google Scholar
• Glare P , AubreyKR , MylesPS. Transition from acute to chronic pain after surgery. Lancet393(10180), 1537–1546 (2019).
   PubMed Web of Science ®Google Scholar
• Boström BM , RambergT , DavisBD , FridlundB. Survey of post-operative patients’ pain management. J. Nurs. Manag.5(6), 341–349 (1997).
   PubMedGoogle Scholar
• De Boer HD , DetricheO , ForgetP. Opioid-related side effects: postoperative ileus, urinary retention, nausea and vomiting, and shivering. A review of the literature. Best Pract. Res. Clin. Anaesthesiol.31(4), 499–504 (2017).
   PubMedGoogle Scholar
• Smith HS , LauferA. Opioid induced nausea and vomiting. Eur. J. Pharmacol.722, 67–78 (2014).
   PubMed Web of Science ®Google Scholar
• Boom M , NiestersM , SartonE , AartsL , SmithTW , DahanA. Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr. Pharm. Des.18(37), 5994–6004 (2012).
   PubMed Web of Science ®Google Scholar
• Schneider JP , KirshKL. Defining clinical issues around tolerance, hyperalgesia, and addiction: a quantitative and qualitative outcome study of long-term opioid dosing in a chronic pain practice. J. Opioid Manag.6(6), 385–395 (2010).
   PubMedGoogle Scholar
• Manchikanti L , HelmS , FellowsB2ndet al. Opioid epidemic in the United States. Pain Physician15(Suppl. 3), Es9–38 (2012).
   PubMed Web of Science ®Google Scholar
• Fernandes AW , KernDM , DattoC , ChenY-W , McleskeyC , TunceliO. Increased burden of healthcare utilization and cost associated with opioid-related constipation among patients with noncancer pain. Am. Health Drug Benefits9(3), 160–170 (2016).
   PubMedGoogle Scholar
• Birnbaum HG , WhiteAG , SchillerM , WaldmanT , ClevelandJM , RolandCL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med.12(4), 657–667 (2011).
   PubMed Web of Science ®Google Scholar
• Florence CS , ZhouC , LuoF , XuL. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med. Care54(10), 901–906 (2016).
   PubMed Web of Science ®Google Scholar
• Opioids. In: LiverTox: Clinical and Research Information on Drug-Induced Liver InjuryNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA, (2012).
   Google Scholar
• Zöllner C . Opioids. In: Analgesia. SteinC (Ed.). Springer, Berlin, Heidelberg, 31–63 (2007).
   Google Scholar
• Waldhoer M , SelenaE , BartlettA , WhistlerJL. Opioid receptors. Annu. Rev. Biochem.73(1), 953–990 (2004).
   PubMedGoogle Scholar
• Gavériaux-Ruff C , KiefferBL. Opioid receptor genes inactivated in mice: the highlights. Neuropeptides36(2–3), 62–71 (2002).
   PubMed Web of Science ®Google Scholar
• Ehrlich AT , KiefferBL , DarcqE. Current strategies toward safer mu opioid receptor drugs for pain management. Expert Opin. Ther. Targets23(4), 315–326 (2019).
   PubMed Web of Science ®Google Scholar
• Peterson YK , LuttrellLM. The diverse roles of arrestin scaffolds in G Protein–coupled receptor signaling. Pharmacol. Rev.69(3), 256–297 (2017).
   PubMed Web of Science ®Google Scholar
• Raehal KM , WalkerJK , BohnLM. Morphine side effects in β-arrestin 2 knockout mice. J. Pharmacol. Exp. Ther.314(3), 1195–1201 (2005).
   PubMed Web of Science ®Google Scholar
• Dewire SM , YamashitaDS , RomingerDHet al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J. Pharmacol. Exp. Ther.344(3), 708–717 (2013).
   PubMed Web of Science ®Google Scholar
• Hill R , DisneyA , ConibearAet al. The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. Br. J. Pharmacol.175(13), 2653–2661 (2018).
   PubMed Web of Science ®Google Scholar
• Yudin Y , RohacsT. The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels. Br. J. Pharmacol.176(17), 3110–3125 (2019).
   PubMed Web of Science ®Google Scholar
• Grim TW , SchmidCL , StahlELet al. A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal. Neuropsychopharmacology45(2), 416–425 (2020).
   PubMed Web of Science ®Google Scholar
• Koblish M , CarrR , SiudaER3rdet al. TRV0109101, a G protein-biased agonist of the μ-opioid receptor, does not promote opioid-induced mechanical allodynia following chronic administration. J. Pharmacol. Exp. Ther.362(2), 254–262 (2017).
   PubMed Web of Science ®Google Scholar
• Raehal KM , SchmidCL , GroerCE , BohnLM. Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol. Rev.63(4), 1001–1019 (2011).
   PubMed Web of Science ®Google Scholar
• Gillis A , GondinAB , KliewerAet al. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci. Signal13(625), (2020).
   PubMed Web of Science ®Google Scholar
• Altarifi AA , DavidB , MuchhalaKH , BloughBE , AkbaraliH , NegusSS. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J. Psychopharmacol.31(6), 730–739 (2017).
   PubMed Web of Science ®Google Scholar
• Liang DY , LiWW , NwaneshiuduC , IrvineKA , ClarkJD. Pharmacological characters of oliceridine, a μ-opioid receptor G-protein-biased ligand in mice. Anesth. Analg.129(5), 1414–1421 (2019).
   PubMed Web of Science ®Google Scholar
• Araldi D , FerrariLF , LevineJD. Mu-opioid receptor (MOR) biased agonists induce biphasic dose-dependent hyperalgesia and analgesia, and hyperalgesic priming in the rat. Neuroscience394, 60–71 (2018).
   PubMed Web of Science ®Google Scholar
• Austin Zamarripa C , EdwardsSR , QureshiHN , YiJN , BloughBE , FreemanKB. The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats. Drug Alcohol Depend.192, 158–162 (2018).
   PubMed Web of Science ®Google Scholar
• Schwienteck KL , FaunceKE , RiceKCet al. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats. Neuropharmacology150, 200–209 (2019).
   PubMed Web of Science ®Google Scholar
• Chen X-T , PitisP , LiuGet al. Structure–activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. J. Med. Chem.56(20), 8019–8031 (2013).
   PubMed Web of Science ®Google Scholar
• Schneider S , ProvasiD , FilizolaM. How oliceridine (TRV-130) binds and stabilizes a μ-opioid receptor conformational state that selectively triggers G protein signaling pathways. Biochemistry55(46), 6456–6466 (2016).
   PubMed Web of Science ®Google Scholar
• Fossler MJ , SadlerBM , FarrellCet al. Oliceridine, a novel G protein-biased ligand at the μ-opioid receptor, demonstrates a predictable relationship between plasma concentrations and pain relief. II: simulation of potential Phase III study designs using a pharmacokinetic/pharmacodynamic model. J. Clin. Pharmacol.58(6), 762–770 (2018).
   PubMed Web of Science ®Google Scholar
• Nafziger AN , ArscottKA , CochraneK , SkobierandaF , BurtDA , FosslerMJ. The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of oliceridine. Clin. Pharmacol. Drug Dev. doi:10.1002/cpdd.750 (2019) ( Epub ahead of print).
   PubMedGoogle Scholar
• Fossler MJ , SadlerBM , FarrellCet al. Oliceridine (TRV130), a novel G protein-biased ligand at the μ-opioid receptor, demonstrates a predictable relationship between plasma concentrations and pain relief. i: development of a pharmacokinetic/pharmacodynamic model. J. Clin. Pharmacol.58(6), 750–761 (2018).
   PubMed Web of Science ®Google Scholar
• Soergel DG , SubachRA , SadlerBet al. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J. Clin. Pharmacol.54(3), 351–357 (2014).
   PubMed Web of Science ®Google Scholar
• Soergel DG , SubachRA , BurnhamNet al. Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain155(9), 1829–1835 (2014).
   PubMed Web of Science ®Google Scholar
• Viscusi ER , WebsterL , KussMet al. A randomized, Phase II study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain. Pain157(1), 264–272 (2016).
   PubMed Web of Science ®Google Scholar
• Singla N , MinkowitzHS , SoergelDGet al. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel μ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J. Pain Res.10, 2413–2424 (2017).
   PubMed Web of Science ®Google Scholar
• Viscusi ER , SkobierandaF , SoergelDG , CookE , BurtDA , SinglaN. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the μ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J. Pain Res.12, 927–943 (2019).
   PubMed Web of Science ®Google Scholar
• Singla NK , SkobierandaF , SoergelDGet al. APOLLO-2: a randomized, placebo and active-controlled Phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the μ-opioid receptor, for management of moderate to severe acute pain following abdominoplasty. Pain Pract.19(7), 715–731 (2019).
   PubMed Web of Science ®Google Scholar
• Bergese SD , BrzezinskiM , HammerGBet al. ATHENA: a Phase III, open-label study of the safety and effectiveness of oliceridine (TRV130), a G-protein selective agonist at the μ-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy. J. Pain Res.12, 3113–3126 (2019).
   PubMed Web of Science ®Google Scholar
• Goudra B , GoudaG , MohinderP. Recent developments in drugs for gi endoscopy sedation. Dig. Dis. Sci. doi:10.1007/s10620-020-06044-5 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Ayad S , DemitrackMA , BurtDAet al. Evaluating the incidence of opioid-induced respiratory depression associated with oliceridine and morphine as measured by the frequency and average cumulative duration of dosing interruption in patients treated for acute postoperative pain. Clin. Drug Investig.40(8), 755–764 (2020).
   PubMed Web of Science ®Google Scholar
• Dahan A , Van DamCJ , NiestersMet al. Benefit and risk evaluation of biased μ-receptor agonist oliceridine versus morphine. Anesthesiology133(3), 559–568 (2020).
   PubMed Web of Science ®Google Scholar
• Bergese S , BerkowitzR , RiderPet al. Low incidence of postoperative respiratory depression with oliceridine compared to morphine: a retrospective chart analysis. Pain Res. Manag.2020, 7492865 (2020).
   PubMed Web of Science ®Google Scholar